Clinical Trial Update: A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients [Phase 3]

View source ↗

Summary

A Phase III study of NTQ5082 capsules for paroxysmal nocturnal hemoglobinuria is planned, with the trial currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• NTQ5082

Snippet

Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Status: NOT_YET_RECRUITING